Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Head and Neck
Lung Cancers
Prostate Cancer
Kidney Cancer
Precision Medicine
Supportive Care
Soft Tissue Sarcoma
Giants Cancer Care

New Phase III Trial

Lisa Schulmeister, RN, MN, APRN-BC, OCN, FAAN
Published Online: Monday, August 19, 2013
Colorectal cancer is recognized as a common cancer and is the third leading cause of cancer mortality. As with many other types of cancer, people who have been treated for colon cancer are at increased risk for developing a new colon cancer. To explore if colorectal cancer recurrence can be reduced after initial treatment, the National Cancer Institute, Southwest Oncology Group, and Cancer Prevention Pharmaceuticals, Inc., recently announced a phase III trial called the Preventing Adenomas of the Colon with Eflornithine and Sulinidac (PACES) trial.The primary objective is to assess whether eflornithine 500 mg or sulindac 150 mg (or both) are effective in reducing the 3-year event rate, defined as high risk adenoma or 2nd primary colorectal cancer, in patients with Stage 0, I, II, and III colon cancer. Both drugs work to lower levels of polyamines, which are naturally-formed molecules that play a role in the development of colorectal cancer. Eflornithine slows the body's production of polyamines and sulindac helps cells eliminate excess polyamines.

The researchers chose these two drugs because of an earlier study that looked at their preventive effects in patients who already had at least one adenoma removed from their colon. In that study, participants who took the drug combination lowered their risk of developing another adenoma over the next three years to less than one third of what it was for those who did not take the drugs. They lowered their chances of developing high-risk adenomas or multiple adenomas during that time by 90%. Information about the trial and patient enrollment criteria are available at
Online CME Activities
Free CME from PER
Clinical Vignettes in Improving Patient Care through Angiogenesis Inhibitors: A Focus on Gastrointestinal Malignancies
Clinical Vignettes in Metastatic Colorectal Cancer: Precision Medicine for Community Oncologists
Evolving Management Strategies for Triple-Negative Breast Cancer
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer
More Reading